Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | PDE4A | P27815 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.32 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL599601 | 1.00 | LMNA (0.40) | LMNAL3MBTL1TDP1PDE4AUSP2 | |
| SCHEMBL6795503 | 1.00 | LMNA (0.40) | LMNAL3MBTL1TDP1PDE4AUSP2 | |
| SCHEMBL25264497 | 1.00 | LMNA (0.40) | LMNAL3MBTL1TDP1PDE4AUSP2 | |
| SCHEMBL28985161 | 1.00 | LMNA (0.40) | LMNAL3MBTL1TDP1PDE4AUSP2 | |
| SCHEMBL98729 | 0.87 | AKR1B1 (0.33) | LMNAL3MBTL1TDP1AKR1B1 | |
| SCHEMBL28197 | 0.87 | AKR1B1 (0.33) | LMNAL3MBTL1TDP1AKR1B1 | |
| SCHEMBL27561548 | 0.87 | AKR1B1 (0.33) | LMNAL3MBTL1TDP1AKR1B1 | |
| Water SCHEMBL28186002 | 0.85 | AKR1B1 (0.32) | LMNAL3MBTL1AKR1B1 | |
| SCHEMBL968310 | 0.81 | LMNA (0.42) | LMNAL3MBTL1TDP1PDE4AUSP2 | |
| SCHEMBL457880 | 0.81 | LMNA (0.42) | LMNAL3MBTL1TDP1PDE4AUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250017950-A1 | COMPOUNDS FOR TREATING MITOCHONDRIAL DNA DISORDERS | UCL BUSINESS LTD (GB) | 2025-01-16 | — | — | US | claimed |
| EP-4433077-A1 | COMPOUNDS FOR TREATING MITOCHONDRIAL DNA DISORDERS | UCL Business Ltd (GB) | 2024-09-25 | — | — | EP | claimed |
| CN-114453428-B | Method for preventing rear-end collision of strip steel in finish rolling and coiling | 首钢京唐钢铁联合有限责任公司 | 2024-05-10 | — | — | CN | claimed |
| CN-116411353-A | Synthesis method of DNA coding compound oxo-glycoside | 成都先导药物开发股份有限公司 | 2023-07-11 | — | — | CN | claimed |
| WO-2023089313-A1 | COMPOUNDS FOR TREATING MITOCHONDRIAL DNA DISORDERS | UCL BUSINESS LTD (GB) | 2023-05-25 | — | — | WO | claimed |
| US-20130184330-A1 | COMPOSITIONS AND METHODS FOR INDUCING CANCER CELL DEATH | UNIVERSITY OF MIAMI (US) | 2013-07-18 | — | — | US | claimed |
| WO-2012024234-A1 | COMPOSITIONS AND METHODS FOR INDUCING CANCER CELL DEATH | UNIVERSITY OF MIAMI (US) | 2012-02-23 | — | — | WO | claimed |
| US-20260009062-A1 | TRANSFER OF C2'-EPIMERIZED SUGARS TO THE AMPHOTERICIN B AGLYCONE | UNIV ILLINOIS (US) | 2026-01-08 | — | — | US | disclosed |
| CN-119730733-A | Kit for promoting developmental myelination | 雀巢产品有限公司 | 2025-03-28 | — | — | CN | disclosed |
| US-12216326-B2 | Optical member driving mechanism | TDK TAIWAN CORP. (TW) | 2025-02-04 | — | — | US | disclosed |
| US-20250017950-A1 | COMPOUNDS FOR TREATING MITOCHONDRIAL DNA DISORDERS | UCL BUSINESS LTD (GB) | 2025-01-16 | — | — | US | disclosed |
| EP-4433077-A1 | COMPOUNDS FOR TREATING MITOCHONDRIAL DNA DISORDERS | UCL Business Ltd (GB) | 2024-09-25 | — | — | EP | disclosed |
| CN-118256607-A | ACGH gene chip and kit for detecting fetal birth defects caused by chromosome microdeletion and microduplication and application thereof | 中山康源基因技术科技有限公司 | 2024-06-28 | — | — | CN | disclosed |
| EP-1986660-A2 | HEXOSE COMPOUNDS TO TREAT CANCER | Board of Regents, The University of Texas System (US) | 2008-11-05 | — | — | EP | disclosed |
| WO-2007101148-A2 | HEXOSE COMPOUNDS TO TREAT CANCER | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2007-09-07 | — | — | WO | disclosed |
| WO-2007100728-A2 | MANNOSE DERIVATIVES FOR KILLING TUMOR CELLS | UNIVERSITY OF MIAMI (US) | 2007-09-07 | — | — | WO | disclosed |
| CN-1771043-A | Treatment of cancer with 2-deoxyglucose | THRESHOLD PHARMACEUTICALS INC (US) | 2006-05-10 | — | — | CN | disclosed |
| US-5994502-A | CONTACTING A PEPTIDE CONTAINING ASPARAGINE IN A GLYCOSYLATION RECOGNITION MOTIF WITH A COMPOUND OF GLUCOSE-MANNOSE-N-ACETYLGLUCOSAMINE-PYROPHOSPHATE-DOLICHOL AND THE ENZYME, ISOLATING FORMED GLYCOPEPTIDE | NATIONAL INSTITUTES OF HEALTH | 1999-11-30 | — | — | US | disclosed |
| US-5721338-A | BIOSYNTHESIS OF GLYCOPEPTIDES | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 1998-02-24 | — | — | US | disclosed |
| WO-1991009971-A1 | CHROMOGENIC 5-POSITION MODIFIED NEURAMINIC ACID SUBSTRATES AND METHODS FOR DIAGNOSING HUMAN INFLUENZA THEREWITH | SYMEX CORP. (US) | 1991-07-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260009062-A1 | TRANSFER OF C2'-EPIMERIZED SUGARS TO THE AMPHOTERICIN B AGLYCONE | ERG28, SLC2A9, GALE | LMNA 1600/4885L3MBTL1 394/4885TDP1 4536/4885 |
| US-20250017950-A1 | COMPOUNDS FOR TREATING MITOCHONDRIAL DNA DISORDERS | POLRMT, TK2, GOT2 | LMNA 2348/4885L3MBTL1 518/4885TDP1 115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.